12/17
09:23 am
bhvn
Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
12/17
08:15 am
bhvn
Biohaven Ltd. (NYSE: BHVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.
Medium
Report
Biohaven Ltd. (NYSE: BHVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.
12/16
07:47 am
bhvn
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates [Yahoo! Finance]
Medium
Report
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates [Yahoo! Finance]
12/16
07:30 am
bhvn
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates
Medium
Report
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates
12/6
07:34 am
bhvn
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting [Yahoo! Finance]
Medium
Report
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting [Yahoo! Finance]
12/6
07:30 am
bhvn
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting
Medium
Report
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting
12/4
12:27 pm
bhvn
Biohaven Ltd. (NYSE: BHVN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $61.00 price target on the stock, up previously from $58.00.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $61.00 price target on the stock, up previously from $58.00.
11/29
07:00 am
bhvn
Biohaven's Revenue Path: SCA And Obesity Therapies [Seeking Alpha]
Low
Report
Biohaven's Revenue Path: SCA And Obesity Therapies [Seeking Alpha]
11/26
08:00 am
bhvn
Biohaven Ltd. (NYSE: BHVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.
Medium
Report
Biohaven Ltd. (NYSE: BHVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.
11/25
12:44 pm
bhvn
Biohaven Ltd. (NYSE: BHVN) had its price target lowered by analysts at Royal Bank of Canada from $66.00 to $58.00. They now have an "outperform" rating on the stock.
Medium
Report
Biohaven Ltd. (NYSE: BHVN) had its price target lowered by analysts at Royal Bank of Canada from $66.00 to $58.00. They now have an "outperform" rating on the stock.
11/25
11:56 am
bhvn
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study [Yahoo! Finance]
Low
Report
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study [Yahoo! Finance]
11/25
07:36 am
bhvn
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity [Yahoo! Finance]
High
Report
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity [Yahoo! Finance]
11/25
07:30 am
bhvn
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
Low
Report
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
11/19
10:14 am
bhvn
XVIVO Wins Two Davey Awards: A Gold and a Silver for Two Animation Programs
Low
Report
XVIVO Wins Two Davey Awards: A Gold and a Silver for Two Animation Programs
11/14
08:15 am
bhvn
Biohaven Ltd. (NYSE: BHVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.
11/13
01:46 pm
bhvn
Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at TD Cowen from $55.00 to $75.00. They now have a "buy" rating on the stock.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at TD Cowen from $55.00 to $75.00. They now have a "buy" rating on the stock.
11/13
10:08 am
bhvn
Biohaven Ltd. (NYSE: BHVN) had its price target lowered by analysts at Royal Bank of Canada from $68.00 to $66.00. They now have an "outperform" rating on the stock.
Medium
Report
Biohaven Ltd. (NYSE: BHVN) had its price target lowered by analysts at Royal Bank of Canada from $68.00 to $66.00. They now have an "outperform" rating on the stock.
11/13
02:25 am
bhvn
Biohaven Non-GAAP EPS of -$1.74 misses by $0.24 Nov. 13, 2024 2:24 AM ET By: Meghavi Singh , SA News Editor [Seeking Alpha]
Medium
Report
Biohaven Non-GAAP EPS of -$1.74 misses by $0.24 Nov. 13, 2024 2:24 AM ET By: Meghavi Singh , SA News Editor [Seeking Alpha]
11/12
04:05 pm
bhvn
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
Low
Report
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
10/23
12:32 pm
bhvn
Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
10/4
09:54 am
bhvn
Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
10/4
02:27 am
bhvn
AbbVie's atogepant set to reach projected worth of $766m in 2026 after accepted NDA from FDA [Yahoo! Finance]
Low
Report
AbbVie's atogepant set to reach projected worth of $766m in 2026 after accepted NDA from FDA [Yahoo! Finance]
10/3
12:23 pm
bhvn
Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at JPMorgan Chase & Co. from $55.00 to $68.00. They now have an "overweight" rating on the stock.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at JPMorgan Chase & Co. from $55.00 to $68.00. They now have an "overweight" rating on the stock.
10/3
08:49 am
bhvn
Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock [Yahoo! Finance]
Medium
Report
Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock [Yahoo! Finance]
10/2
04:05 pm
bhvn
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Low
Report
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares